Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases

Olga Vaksman, Ben Davidson*, Claes Tropé, Reuven Reich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

The objective of this study was to analyze the expression and clinical role of calreticulin, a multifunctional Ca2+-binding chaperone of the endoplasmic reticulum, in advanced-stage high-grade serous ovarian carcinoma. Cellular calreticulin messenger RNA (mRNA) and protein expression was investigated in 102 and 56 tumors, respectively, using reverse transcriptase polymerase chain reaction and Western blotting. Secreted calreticulin level was further analyzed in 31 effusion supernatants. Results were analyzed for association with anatomical site and clinicopathologic parameters, including survival. Calreticulin mRNA and protein were detected in 101 of 102 and 55 of 56 tumors, respectively. Calreticulin mRNA was overexpressed in solid metastases (n = 15) compared with effusions (n = 55) and primary carcinomas (n = 32; P =.009), whereas protein expression was significantly higher in solid metastases and primary carcinomas compared with effusion specimens (P =.007). Secreted calreticulin levels were higher in peritoneal compared with pleural effusions (P =.02). Higher cellular calreticulin protein expression in effusions was associated with better response to chemotherapy at diagnosis (P =.037). Calreticulin mRNA and protein expression was unrelated to patient survival. In conclusion, calreticulin is frequently expressed in serous ovarian carcinoma cells at all anatomical sites, but expression is reduced in effusions. Calreticulin protein levels in effusions may be predictive of chemotherapy response at diagnosis.

Original languageEnglish
Pages (from-to)2677-2683
Number of pages7
JournalHuman Pathology
Volume44
Issue number12
DOIs
StatePublished - Dec 2013

Keywords

  • Calreticulin
  • Chemotherapy
  • Ovarian cancer
  • Survival
  • Tumor progression

Fingerprint

Dive into the research topics of 'Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases'. Together they form a unique fingerprint.

Cite this